NICE recommends Pfizer’s Vizimpro for treating NSCLC
Not long ago, Pfizer’s Vizimpro (dacomitinib) a tyrosine kinase inhibitor (TKI), was approved as a first-line monotherapy treatment for adult patients living with locally advanced or metastatic non-small lung cancer (NSCLC). As evaluated by the American Cancer Society, the non-small lung cancer incidence in the United States in 2018 was found to be 234,030 (121,680 in men and 112,350 in women) new cases with 154,050 deaths. Lately, the UK’s National Institute for Health and Care Excellence (NICE) also approved its use once daily to adults. Earlier, Vizimpro did not get approval from NICE due to its cost-ineffecti...
